The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans

Life Sciences

Volumn 91, Issue 13-14, 2012, Pages 743-748

  Seed, Alison ^a   Kuc, Rhoda E ^b   Maguire, Janet J ^b   Hillier, Christopher ^c   Johnston, Fiona ^c   Essers, Hans ^d   De Voogd, Hanka J ^d   McMurray, John ^a   Davenport, Anthony P ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^d Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Atrial natriuretic peptides big endothelin 1; C terminal fragment (CTF); Daglutril; Endothelin converting enzyme (ECE); Endothelin 1; Neutral endopeptidase (NEP); SLV 306

Indexed keywords

ATRIAL NATRIURETIC FACTOR; DAGLUTRIL; ENDOTHELIN 1; MEMBRANE METALLOENDOPEPTIDASE; PLACEBO;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORMAL HUMAN; PROTEIN BLOOD LEVEL; SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ASPARTIC ACID ENDOPEPTIDASES; ATRIAL NATRIURETIC FACTOR; BENZAZEPINES; BLOOD PRESSURE; DOUBLE-BLIND METHOD; ENDOTHELIN-1; HUMANS; MALE; METALLOENDOPEPTIDASES; NEPRILYSIN; YOUNG ADULT;

EID: 84867574381     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.03.022     Document Type: Conference Paper

References (54)

1. S. Ando, M.A. Rahman, G.C. Butler, B.L. Senn, and J.S. Floras Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin Hypertension 6 1995 1160 1166
2. B. Battistini, P. Daull, and A.Y. Jeng CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme Cardiovasc Drug Rev 23 2005 317 330
3. M. Bayes, X. Rabasseda, and J.R. Prous Gateways to clinical trials Methods Find Exp Clin Pharmacol 25 2003 317 340
4. C. Bucchwalder-Csajka, T. Buclin, H.R. Brunner, and J. Biollaz Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system Br J Clin Pharmacol 48 1999 594 604
5. H.H. Chen, and J.C. Burnett Jr. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials Proc Assoc Am Physicians 111 1999 406 416
6. A.P. Davenport International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature Pharmacol Rev 54 2002 219 226
7. A.P. Davenport, and J.J. Maguire Endothelin Handb Exp Pharmacol 2006 295 329
8. A.P. Davenport, and J.J. Maguire Pharmacology of renal endothelin receptors Contrib Nephrol 172 2011 1 17
9. N. Dhaun, D.M. Pollock, J. Goddard, and D.J. Webb Selective and mixed endothelin receptor antagonism in cardiovascular disease Trends Pharmacol Sci 28 2007 573 579
10. K. Dickstein, H.J. De Voogd, M.P. Miric, R. Willenbrock, V. Mitrovic, and R. Pacher Effect of single doses of SLV-306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure Am J Cardiol 94 2004 237 239
11. V. Dive, C.F. Chang, A. Yiotakis, and E.D. Sturrock Inhibition of zinc metallopeptidases in cardiovascular disease - from unity to trinity, or duality? Curr Pharm Des 15 2009 3606 3621
12. P. D'Orleans-Juste, M. Houde, G.A. Rae, G. Bkaily, E. Carrier, and E. Simard Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies Vascul Pharmacol 49 2008 51 62
13. N. Emoto, and M. Yanagisawa Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum J Biol Chem 270 1995 15262 15268
14. B. Favrat, M. Burnier, J. Nussberger, J.M. Lecomte, R. Brouard, and B. Waeber Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension J Hypertens 7 1995 797 804
15. M.H. Fecteau, J.C. Honore, M. Plante, J. Labonte, G.A. Rae, and P. D'Orleans-Juste Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo Hypertension 46 2005 87 92
16. C.J. Ferro, J.C. Spratt, W.G. Haynes, and D.J. Webb Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo Circulation 97 1998 2323 2330
17. M.D. Flather, S. Yusuf, L. Kober, M. Pfeffer, A. Hall, and G. Murray Long-term ACE inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients Lancet 355 2000 1575 1581
18. R. Garg, and S. Yusuf Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials JAMA 273 1995 1450 1456
19. M.F. Hand, W.G. Haynes, and D.J. Webb Reduced endogenous endothelin-1-mediated vascular tone in chronic renal failure Kidney Int 55 1999 613 620
20. W.G. Haynes, and D.J. Webb Contribution of endogenous generation of endothelin-1 to basal vascular tone Lancet 344 1994 852 854
21. W.G. Haynes, C.E. Ferro, and D.J. Webb Physiologic role of endothelin in maintenance of vascular tone in humans J Cardiovasc Pharmacol 26 1995 S183 S185
22. A.G. Jardine, J.M. Connell, D. Northridge, S.G. Dilly, N.J. Cussans, and G. Davidson The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans Am J Hypertens 3 1990 661 667
23. P. Johnstrom, T.D. Fryer, H.K. Richards, J.J. Maguire, J.C. Clark, and J.D. Pickard Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver Br J Pharmacol 159 2010 812 819
24. M. Kentsch, W. Otter, C. Drummer, A. Nötges, R. Gerzer, and G. Müller-Esch Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure Eur J Clin Pharmacol 51 1996 269 272
25. L. Ling, J.J. Maguire, and A.P. Davenport Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer Br J Pharmacol 2012 10.1111/j.1476-5381.2011.01786.x
26. M.P. Love, W.G. Haynes, G.A. Gray, D.J. Webb, and J.J. McMurray Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors Circulation 94 1996 2131 2137
27. J.J. Maguire, and A.P. Davenport Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease Br J Pharmacol 125 1998 238 240
28. J.J. Maguire, C.M. Johnson, J.W. Mockridge, and A.P. Davenport Endothelin converting enzyme (ECE) activity in human vascular smooth muscle Br J Pharmacol 122 1997 1647 1654
29. J.J. Maguire, R.E. Kuc, and A.P. Davenport Vasoconstrictor activity of novel endothelin peptide, ET-1(1-31), in human mammary and coronary arteries in vitro Br J Pharmacol 134 2001 1360 1366
30. T.A. McDonagh, S.D. Robb, D.R. Murdoch, J.J. Morton, I. Ford, and C.E. Morrison Biochemical detection of left-ventricular systolic dysfunction Lancet 351 1998 9 13
31. G. McDowell, W. Coutie, C. Shaw, K.D. Buchanan, A.D. Struthers, and D.P. Nicholls The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides Br J Clin Pharmacol 43 1997 329 332
32. K. Naruse, M. Naruse, Y. Watanabe, I. Yoshihara, K. Ohsumi, and J. Horiuchi Molecular form of immunoreactive endothelin in plasma and urine of normal subjects and patients with various disease states J Cardiovasc Pharmacol 17 Suppl. 7 1991 S506 S508
33. D.E. Newby, T. McDonagh, P.F. Currie, D.B. Northridge, N.A. Boon, and H.J. Dargie Candoxatril improves exercise capacity in patients with chronic heart failure receiving angiotensin converting enzyme inhibition Eur Heart J 12 1998 1808 1813
34. D.B. Northridge, A.G. Jardine, C.T. Alabaster, P.L. Barclay, J.M. Connell, and H.J. Dargie Effects of UK 69 5788: a novel atriopeptidase inhibitor Lancet 2 1989 591 593
35. D.B. Northridge, P.F. Currie, D.E. Newby, J.J. McMurray, M. Ford, and N.A. Boon Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure Eur J Heart Fail 1 1999 67 72
36. J.E. O'Connell, A.G. Jardine, G. Davidson, and J.M. Connell Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension J Hypertens 3 1992 271 277
37. M.J. Palmer Endothelin receptor antagonists: status and learning 20 years on Prog Med Chem 47 2009 203 237
38. C. Plumpton, W.G. Haynes, D.J. Webb, and A.P. Davenport Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm Br J Pharmacol 116 1995 1821 1828
39. A.M. Richards, I.G. Crozier, E.A. Espiner, H. Ikram, T.G. Yandle, and T. Kosoglou Acute inhibition of endopetidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure J Cardiovasc Pharmacol 20 1992 735 741
40. A.M. Richards, E.A. Wittert, T.G. Espiner, T.G. Yandle, H. Ikram, and C. Frampton Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers Circ Res 71 1992 1501 1507
41. A.M. Richards, G.A. Wittert, I.G. Crozier, E.A. Spiner, T.G. Yandle, and H. Ikram Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II J Hypertens 4 1993 407 416
42. P. Rousso, T. Buclin, J. Nussberger, F. Brunner-Ferber, H.R. Brunner, and J. Biollaz Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I and angiotensin II challenges in healthy volunteers J Cardiovasc Pharmacol 31 1998 408 417
43. F.D. Russell, and A.P. Davenport Secretory pathways in endothelin synthesis Br J Pharmacol 126 1999 391 398
44. J.S. Russell, H. Chi, and P.E. Ward Endothelin-1 metabolism by neutral endopeptidase-24.11 identified in cultured human skeletal muscle myocytes and fibroblasts Immunopharmacology 32 1996 180 182
45. F.D. Russell, J.N. Skepper, and A.P. Davenport Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin-converting enzyme Circ Res 83 1998 314 321
46. F.D. Russell, J.N. Skepper, and A.P. Davenport Evidence using immuno-electron microscopy for the regulated and constitutive pathways in the transport and release of endothelin J Cardiovasc Pharmacol 31 1998 424 430
47. J.A. Schirger, J.A. Grantham, I.J. Kullo, M. Jougasaki, P.W. Wennberg, and H.H. Chen Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition J Am Coll Cardiol 35 2000 796 801
48. R. Tabrizchi SLV-306. Solvay Curr Opin Investig Drugs 4 2003 329 332
49. C. Thöne-Reinke, K. Simon, C.M. Richter, M. Godes, H.H. Neumayer, and D. Thormählen Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV-306 reduces proteinuria and urinary albumin excretion in diabetic rats J Cardiovasc Pharmacol 44 Suppl. 1 2004 S76 S79
50. J.L. Vachiéry, and A. Davenport The endothelin system in pulmonary and renal vasculopathy: les liaisons dangereuses Eur Respir Rev 18 2009 260 271
51. I. Van der Meer, A. Benigni, A. Parvanova, I. Iliev, S. Sharma, and J. Cruz Pressure control by combined ECE/NEP inhibitor on top of losartan: a randomized, cross-over, placebo-controlled clinical trial in patients with type 2 diabetes and albuminuria Twelfth International Conference on Endothelin 2011 50
52. D. Xu, N. Emoto, A. Giaid, C. Slaughter, S. Kaw, and D. deWit ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1 Cell 78 1994 473 485
53. H. Yanagisawa, R.E. Hammer, J.A. Richardson, N. Emoto, S.C. Williams, and S. Takeda Disruption of ECE-1 and ECE-2 reveals a role for endothelin- converting enzyme-2 in murine cardiac development J Clin Invest 105 2000 1373 1382
54. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153